Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Butyrate Clear all
Completed Phase 4 Interventional Results available

Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

NCT04006925
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Parkinson Disease
Interventions
Sodium Oxybate, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Early Phase 1 Interventional

Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin

NCT03589898
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Gabapentin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
13 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 4, 2026, 9:18 AM EDT
Recruiting Phase 1 Interventional

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT06191887
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
Interventions
Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

NCT00877006
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
bendamustine, rituximab, vincristine, prednisone, cyclophosphamide, doxorubicin
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
79
States / cities
Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Early Phase 1 Interventional

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

NCT03295240
View directory record Official record
Conditions
Mantle Cell Lymphoma, Lymphoma
Interventions
BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 4, 2026, 9:18 AM EDT
Withdrawn Early Phase 1 Interventional

Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia

NCT03626727
View directory record Official record
Conditions
Hypersomnia, Narcolepsy, Traumatic Brain Injury
Interventions
Sodium Oxybate Oral Solution [Xyrem]
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Determine the Effect of Synbiotics in Patients With Pre-diabetes

NCT04428606
View directory record Official record
Conditions
PreDiabetes
Interventions
Metabolic Rheostat, Butyrate Ultra, Placebo
Dietary Supplement
Lead sponsor
Zhaoping Li
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 4, 2026, 9:18 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin

NCT00187707
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 4, 2026, 9:18 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

LXRA Gene Polymorphisms and Response to Fenofibrate

NCT00644592
View directory record Official record
Conditions
Healthy
Interventions
Fenofibrate capsule daily for 4 weeks, Fenofibrate
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 4, 2026, 9:18 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Results available

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

NCT01366196
View directory record Official record
Conditions
Lumbar Spinal Fusions
Interventions
Pregabalin 150 mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
21 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors

NCT01005108
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia

NCT00588159
View directory record Official record
Conditions
Pain
Interventions
Gabapentin, Diphenhydramine
Drug
Lead sponsor
Michelle Kinney
Other
Eligibility
45 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 4, 2026, 9:18 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty

NCT03498261
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Gabapentin, Placebos
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy

NCT02607254
View directory record Official record
Conditions
Idiopathic Small Fiber Neuropathy
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics

NCT03220776
View directory record Official record
Conditions
Alcohol Use Disorder, Bipolar Disorder
Interventions
N-Acetylcysteine, Gabapentin, Placebo Oral Tablet
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

NCT01472380
View directory record Official record
Conditions
Healthy
Interventions
efavirenz, fenofibric acid 105 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Phase 4 Interventional Results available

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

NCT02260388
View directory record Official record
Conditions
Cryptogenic Sensory Polyneuropathy
Interventions
Nortriptyline, Duloxetine, Pregabalin, Mexiletine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 4, 2026, 9:18 AM EDT
Not yet recruiting Phase 1 Interventional

Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor

NCT07041203
View directory record Official record
Conditions
Spasmodic Dysphonia, Laryngeal Dystonia, Voice Tremor
Interventions
sodium oxybate
Drug
Lead sponsor
Kristina Simonyan
Other
Eligibility
21 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Results available

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT01088048
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
11
States / cities
Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 4, 2026, 9:18 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Pregabalin for Central Sensitization in TKA

NCT05460871
View directory record Official record
Conditions
Osteo Arthritis Knee, Central Nervous System Sensitization
Interventions
Pregabalin 75mg
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 4, 2026, 9:18 AM EDT
Recruiting Phase 4 Interventional

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

NCT05302999
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 4, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

NCT00856830
View directory record Official record
Conditions
Small Cell Lung Cancer, Extensive Stage Lung Cancer, Chemonaive
Interventions
Novel Drug Combination
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Sep 4, 2026, 9:18 AM EDT